Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy

Samuel J. Taylor, Wallace Y. Langdon

Research output: Contribution to journalArticlepeer-review

Abstract

Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).

Original languageEnglish (US)
Article numbere1378156
JournalMolecular and Cellular Oncology
Volume4
Issue number6
DOIs
StatePublished - Nov 2 2017
Externally publishedYes

Keywords

  • FLT3
  • acute myeloid leukemia
  • chemotherapy
  • hematopoietic progenitors
  • myelosuppression
  • quizartinib

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy'. Together they form a unique fingerprint.

Cite this